Akhil Santhosh: Pacritinib Versus Ruxolitinib in Myelofibrosis With Thrombocytopenia
Akhil Santhosh, Consultant Medical Oncologist at Baby Memorial Hospitals, shared a post on X about a recent article by Claire N. Harrison et al., published in JCO Oncology Advances, adding:
“Efficacy and Safety Outcomes With Pacritinib Versus Ruxolitinib in Patients With Myelofibrosis and Thrombocytopenia: Analysis of Data From the Phase III PERSIST-2 Study, JCO Oncology Advances.”
Title: Efficacy and Safety Outcomes With Pacritinib Versus Ruxolitinib in Patients With Myelofibrosis and Thrombocytopenia: Analysis of Data From the Phase III PERSIST-2 Study
Authors: Claire N. Harrison, Prithviraj Bose, Ruben Mesa, Aaron T. Gerds, Stephen T. Oh, Marta Sobas, Valentín Garcia-Gutierrez, Christof Scheid, Alessandro Maria Vannucchi, Jean-Jacques Kiladjian, Vikas Gupta, Abdulraheem Yacoub, David Lavie, Purvi Suthar, Karisse Roman-Torres, Sarah A. Buckley, John Mascarenhas
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week